Cat. No. 4175
Chemical Name: N-3-Pyridinyl-4-[[3-[[5-(trifluorom
Biological ActivitySelective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM). Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. Displays no activity at FAAH-2 (IC50 >10 μM).
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Ahn et al (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem.Biol. 16 411. PMID: 19389627.
Ahn et al (2009) Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin.Drug Discov. 4 763. PMID: 20544003.
If you know of a relevant reference for PF 3845 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PF 3845 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PF 3845, supplier, pfizer, cannabinoid, receptors, fatty, acid, amide, hydrolase, FAAH, inhibitors, inhibits, PF3845, Tocris Bioscience, Fatty Acid Amide Hydrolase Inhibitor products